Literature DB >> 24470011

Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy.

James J Harding1, Christopher A Barker, Richard D Carvajal, Jedd D Wolchok, Paul B Chapman, Mario E Lacouture.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24470011      PMCID： PMC4879708          DOI： 10.1200/JCO.2013.49.3528

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  17 in total

Review 1.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.

Authors:  Søren M Bentzen
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

2.  Angiosarcoma mimicking cutis verticis gyrata.

Authors:  J E Kim; K H Choi; S J Kang; E J Seo; C K Park; B K Cho; H Kang
Journal:  Clin Exp Dermatol       Date:  2011-04-20       Impact factor: 3.470

3.  Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.

Authors:  Georgina V Long; Uwe Trefzer; Michael A Davies; Richard F Kefford; Paolo A Ascierto; Paul B Chapman; Igor Puzanov; Axel Hauschild; Caroline Robert; Alain Algazi; Laurent Mortier; Hussein Tawbi; Tabea Wilhelm; Lisa Zimmer; Julie Switzky; Suzanne Swann; Anne-Marie Martin; Mary Guckert; Vicki Goodman; Michael Streit; John M Kirkwood; Dirk Schadendorf
Journal:  Lancet Oncol       Date:  2012-10-08       Impact factor: 41.316

4.  A case of vemurafenib-induced keratosis pilaris-like eruption.

Authors:  Connie M Wang; Kristy F Fleming; Sylvia Hsu
Journal:  Dermatol Online J       Date:  2012-04-15

5.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors:  Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal:  Nature       Date:  2010-02-03       Impact factor: 49.962

6.  Analysis of dermatologic events in vemurafenib-treated patients with melanoma.

Authors:  Mario E Lacouture; Madeleine Duvic; Axel Hauschild; Victor G Prieto; Caroline Robert; Dirk Schadendorf; Caroline C Kim; Christopher J McCormack; Patricia L Myskowski; Olivia Spleiss; Kerstin Trunzer; Fei Su; Betty Nelson; Keith B Nolop; Joseph F Grippo; Richard J Lee; Matthew J Klimek; James L Troy; Andrew K Joe
Journal:  Oncologist       Date:  2013-03-01

7.  Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report.

Authors:  Jee Min Lee; Urvi N Mehta; Ly H Dsouza; Beverly Ashleigh Guadagnolo; Deborah L Sanders; Kevin B Kim
Journal:  Melanoma Res       Date:  2013-04       Impact factor: 3.599

8.  Cutis verticis gyrata: unusual chloromatous disease in acute myelogenous leukemia.

Authors:  B D Cheson; R M Christiansen
Journal:  Am J Hematol       Date:  1980       Impact factor: 10.047

9.  RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

Authors:  Fei Su; Amaya Viros; Carla Milagre; Kerstin Trunzer; Gideon Bollag; Olivia Spleiss; Jorge S Reis-Filho; Xiangju Kong; Richard C Koya; Keith T Flaherty; Paul B Chapman; Min Jung Kim; Robert Hayward; Matthew Martin; Hong Yang; Qiongqing Wang; Holly Hilton; Julie S Hang; Johannes Noe; Maryou Lambros; Felipe Geyer; Nathalie Dhomen; Ion Niculescu-Duvaz; Alfonso Zambon; Dan Niculescu-Duvaz; Natasha Preece; Lídia Robert; Nicholas J Otte; Stephen Mok; Damien Kee; Yan Ma; Chao Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Hoa Nguyen; Mark Kockx; Luc Andries; Brian Lestini; Keith B Nolop; Richard J Lee; Andrew K Joe; James L Troy; Rene Gonzalez; Thomas E Hutson; Igor Puzanov; Bartosz Chmielowski; Caroline J Springer; Grant A McArthur; Jeffrey A Sosman; Roger S Lo; Antoni Ribas; Richard Marais
Journal:  N Engl J Med       Date:  2012-01-19       Impact factor: 91.245

10.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962
View more
  14 in total

1.  BRAF V600 Mutation and BRAF Kinase Inhibitors in Conjunction With Stereotactic Radiosurgery for Intracranial Melanoma Metastases: A Multicenter Retrospective Study.

Authors:  Panagiotis Mastorakos; Zhiyuan Xu; James Yu; Judith Hess; Jack Qian; Ajay Chatrath; Davis G Taylor; Douglas Kondziolka; Ronald Warnick; Veronica Chiang; Jason Sheehan
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

2.  Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia.

Authors:  Nina Lang; Florian Sterzing; Alexander H Enk; Jessica C Hassel
Journal:  Strahlenther Onkol       Date:  2014-06-28       Impact factor: 3.621

3.  An Overlap of Secondary Cutis Verticis Gyrata, Folliculitis Decalvans, Folliculitis Keloidalis Nuchae and the Use of Dreadlocks: The Role of Inflammation due to Traction.

Authors:  Luiza Alonso Pereira; Marcelo Teixeira; Jhessica Andrade; Maíra Rochael; Maria Fernanda Reis Gavazzoni-Dias
Journal:  Skin Appendage Disord       Date:  2016-09-30

4.  [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors].

Authors:  R Gutzmer; J C Hassel; K C Kähler; C Loquai; R Mössner; S Ugurel; L Zimmer; Für Komitee Kutane Nebenwirkungen Ado der das Ado
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

5.  [Developmental abnormalities and nevi of the scalp].

Authors:  V Behle; H Hamm
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

6.  LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.

Authors:  Kamran A Ahmed; Jessica M Freilich; Sarah Sloot; Nicholas Figura; Geoffrey T Gibney; Jeffrey S Weber; Siriporn Sarangkasiri; Prakash Chinnaiyan; Peter A Forsyth; Arnold B Etame; Nikhil G Rao
Journal:  J Neurooncol       Date:  2014-12-18       Impact factor: 4.130

7.  A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Authors:  James J Harding; Federica Catalanotti; Rodrigo R Munhoz; Donavan T Cheng; Amin Yaqubie; Nicole Kelly; Gregory C McDermott; Romona Kersellius; Taha Merghoub; Mario E Lacouture; Richard D Carvajal; Katherine S Panageas; Michael F Berger; Neal Rosen; David B Solit; Paul B Chapman
Journal:  Oncologist       Date:  2015-05-08

Review 8.  Safety and Tolerability of Metastasis-Directed Radiation Therapy in the Era of Evolving Systemic, Immune, and Targeted Therapies.

Authors:  Elizabeth Guimond; Chiaojung Jillian Tsai; Ali Hosni; Grainne O'Kane; Jonathan Yang; Aisling Barry
Journal:  Adv Radiat Oncol       Date:  2022-07-14

Review 9.  Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Authors:  Christopher J Anker; Kenneth F Grossmann; Michael B Atkins; Gita Suneja; Ahmad A Tarhini; John M Kirkwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-06-01       Impact factor: 7.038

10.  A case of cutis verticis gyrata related to pregnancy.

Authors:  Xulin Li; Lingna Chen; Jixiang Xu; Xia Xiong; Yongqiong Deng
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 [SEASON]       Impact factor: 2.545
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.